about
Medical management of brain tumors and the sequelae of treatment.Bevacizumab for the treatment of recurrent glioblastoma.Chemotherapy for intracranial ependymoma in adultsTemozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective studyAn open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.Adult primary intradural spinal cord tumors: a review.Temozolomide or bevacizumab for spinal cord high-grade gliomas.Spinal drop metastasis in myxopapillary ependymoma: a case report and a review of treatment options.Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma.Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.Surgical resection of fourth ventricular ependymomas: case series and technical nuances.Extraneural ependymoma: distant bone, lung, liver, and lymph node metastases following bevacizumab.Super-selective basilar artery infusion of bevacizumab and cetuximab for multiply recurrent pediatric ependymoma.Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First ReportAngiogenesis and angiogenic tyrosine kinase receptor expression in pediatric brain tumors.Intramedullary ependymoma: long-term outcome after surgery.A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.Clinical response associated with radiographic regression of a cervicomedullary ependymoma in a NF2 patient treated by bevacizumab.A case of anaplastic clear-cell ependymoma presenting with high erythropoietin concentration and 1p/19q deletions.Shared molecular targets in pediatric gliomas and ependymomas.Pathogenesis and management of type 2 neurofibromatosis
P2860
Q26992174-6128025D-D45F-4DF3-B0C0-0A236DE78174Q34982777-A8C6C1EA-3654-4817-B478-E3B7358C6516Q35997691-B12A65D4-CFAE-4055-A257-4FBB431F46DBQ36493834-76101840-BB03-44BF-BE3D-E2948C6AF5AEQ37193464-92681B69-1FFA-49BF-9485-DEE145BB058BQ37766531-C6BD1BE8-33A4-4886-BB0F-8478BCD3CC2DQ37843792-4C9355CE-4A3A-4AB7-9349-A37997DB8C62Q38017139-1B03C1EF-3F71-415E-89F6-7F71AFC01C7AQ38227174-9499EA53-227D-4F92-B139-A0A55E4D0C66Q38399886-47139E6C-6707-4D46-9866-266ED0544F32Q38586612-A4135832-677E-4A06-A066-29ACBC46918FQ38990024-41CE9134-5481-4F13-92FE-91D38961D967Q39552962-34E3E099-9D8B-4B35-9E67-64CBF2841D00Q41900982-8AF27913-D172-4F6A-A1F2-D2347CAEF0AEQ42588077-F12760E1-E4C9-4F5F-BFBD-3F05D84628B5Q44819993-F9C81BAA-90EB-45B8-836D-BD8926CFCF8CQ47245690-FCD3FE6A-919E-4D28-87B5-CBC9A1257411Q48538147-1FDE7164-E34B-48E7-99F4-DD0BD5F25A02Q55459856-2C89BBC0-248A-48D4-B0E3-42A7E660D508Q55463022-A7586CD4-05B0-4BAA-BF03-EB6C2E1E5814Q55463435-1FF1B4A7-10B9-4398-8B13-464A60BA5404Q57266478-18CCBA84-022F-45F8-9343-81D706F4F39E
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Bevacizumab for recurrent ependymoma.
@en
Bevacizumab for recurrent ependymoma.
@nl
type
label
Bevacizumab for recurrent ependymoma.
@en
Bevacizumab for recurrent ependymoma.
@nl
prefLabel
Bevacizumab for recurrent ependymoma.
@en
Bevacizumab for recurrent ependymoma.
@nl
P2093
P2860
P1433
P1476
Bevacizumab for recurrent ependymoma
@en
P2093
A B Lassman
E A Woyshner
T F Cloughesy
P2860
P304
P356
10.1212/WNL.0B013E3181C1DF34
P407
P577
2009-11-01T00:00:00Z